Stock price performance of Transgenomic, Inc. is analyzed for various periods using several stock trading signals. In this case, The stock price has rallied 294.74% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 97.89% . Looking at the past 52 week period, the stock price is up at 10.62% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Transgenomic, Inc. has a negative value of -51.3 compared to overall market performance. For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a 20-day Moving Average of 29.82% and the 50-Day Moving Average is 95.18%.The 200 Day SMA reached 71.66%
Transgenomic, Inc. is having a Relative Strength Index of 57.96 which indicates the stock is not yet over sold or over bought based on the technical indicators. Transgenomic, Inc. (NASDAQ:TBIO) has climbed 5.6% in the past week and advanced 167.86% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 5.48% and the outperformance has advanced to 165.47% for the last 4 weeks period.
Company has reported several Insider transactions to the SEC, on Jan 11, 2016, Randal J Kirk (10% owner) purchased 4,474,825 shares at 1.00 per share price.
Transgenomic, Inc. (NASDAQ:TBIO) : On Friday heightened volatility was witnessed in Transgenomic, Inc. (NASDAQ:TBIO) which led to swings in the share price. The stock opened for trading at $0.7 and hit $0.7998 on the upside , eventually ending the session at $0.75, with a gain of 10.29% or 0.07 points. The heightened volatility saw the trading volume jump to 2,450,985 shares. The 52-week high of the share price is $1.59 and the company has a market cap of $19 million. The 52-week low of the share price is at $0.151 .
Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variations in the human genetic code. The company believes its WAVE System, which incorporates its proprietary DNASep separation column and associated software, chemical reagents and other consumable items, will become a leading tool to analyze genetic mutations. The WAVE System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other techniques.